International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2022 - IJCMAS--ICV 2022: 95.28 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020] For more details click here

Login as a Reviewer

See Guidelines to Authors
Current Issues
Download Publication Certificate

Original Research Articles                      Volume : 7, Issue:4, April, 2018

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : /
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2018.7(4): 1548-1558

Incidence and Outcome of Surfactant Therapy in Premature Neonates in ICU of KAMC
Farhan A. Enezi1, Sreekanth Mohan1, Khalid Fuad Alghamdi1, Abdulrhman Mubarak D. Alenzi1, Khalid Ahmed Alrashidi1, Abdullah Abdulaziz A. Almajed1, Faisal Eid Alqithami1, Winnie Philip2 and Shoeb Qureshi2*
1Respiratory Therapy Department, College of Applied Medical Sciences, King Saud Bin Abdulaziz University, Riyadh, Saudi Arabia
2Research Department, College of Applied Medical Sciences, King Saud Bin Abdulaziz University, Riyadh, Saudi Arabia
*Corresponding author

Lung surfactant plays a key role in adequate pulmonary function throughout life. Since Surfactant replacement therapy has been introduced in 1980s, it has proven its effect in premature neonates with surfactant deficiency. Since surfactant therapy is important in various respiratory conditions in premature neonates, this proposed study reviews the incidence, outcome & their clinical issues in surfactant replacement therapy. The objective of the study is to assess the outcome of surfactant therapy in premature neonates, to find out the length of hospital stay. The secondary objective is to find the mortality rate, the effect of early administration of surfactant in premature surfactant deficient neonates. The study was conducted in neonatal intensive care units of King AbdulAziz Medical City (KAMC), Riyadh and study subjects include premature neonates undergone surfactant therapy in ICU. A sample size of 110 neonates from a population of 150 premature neonates in neonatal ICU of KAMC was selected. Out of the total 109 subjects, 69 were males and 40 were females. The mean gestational age was 30 weeks. The majority (n=83, 76.15%) had Respiratory Distress Syndrome (RDS). Subjects were treated with surfactant replacement therapy with either survanta (50.5%) or Infasurf (49.5%). The mean APGAR scoring at 1 and 6 minutes was statistically significant (P=0.001). Vital signs such as temperature (sd-0.58, P=0.017), respiratory rate (sd-15.86, p=0.001), and heart rate (sd-17.84, p = 0.046) compared with improved and expired subjects and were statistically significant. Arterial blood gas in pre and post surfactant therapy was statistically significant with pH (p=0.001), Pco2 (p=0.001), and base excess (p=0.001). The administration of surfactant therapy can improve the total outcome of premature infants with respiratory distress. This study favors early use and benefits of surfactant therapy which has proven by many other relevant articles published earlier. This study shows good results after administration of surfactants like survanta and infasurf.

Keywords: Premature neonates, Surfactant deficiency, Respiratory distress, Survanta, Infasurf

Download this article as Download

How to cite this article:

Farhan A. Enezi, Sreekanth Mohan, Khalid Fuad Alghamdi, Abdulrhman Mubarak D. Alenzi, Khalid Ahmed Alrashidi, Abdullah Abdulaziz A. Almajed, Faisal Eid Alqithami, Winnie Philip and Shoeb Qureshi. 2018. Incidence and Outcome of Surfactant Therapy in Premature Neonates in ICU of KAMC.Int.J.Curr.Microbiol.App.Sci. 7(4): 1548-1558. doi:
Copyright: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.